“The Father of Cannabis Research” Raphael Mechoulam to be Honored with First Lifetime Achievement Award, $10,000 Research Grant at New York Arcview Investor Forum

September 20, 2019 |

4 min read

Pioneering Organic Chemist, Professor of Medicinal Chemistry First to Isolate Cannabinoids Leading to the Breakthrough Discoveries of the Endocannabinoid System, Total Synthesis of THC in 1960s

Sept. 20, 2019 14:50 UTC

Pioneering Organic Chemist, Professor of Medicinal Chemistry First to Isolate Cannabinoids Leading to the Breakthrough Discoveries of the Endocannabinoid System, Total Synthesis of THC in 1960s

SAN FRANCISCO--(BUSINESS WIRE)-- The Arcview Group will honor “The Father of Cannabis Research” with a Lifetime Achievement Award and a $10,000 research grant in their first annual cannabis awards presentation at the Arcview Investor Forum: The Evolution of Cannabis: 2020 in New York on Thursday, October 3, 2019, at 7:00 p.m.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005372/en/

Raphael Mechoulam - The Father of Cannabis Research (Photo: Business Wire)

Raphael Mechoulam’s contribution to our understanding and ability to use the cannabis plant for positive benefits is immeasurable. He is being recognized for his cutting-edge cannabis research and breakthrough discovery of THC, one of at least 113 cannabinoids identified in the cannabis plant.

Arcview will be preserving and continuing to honor the invaluable work and contributions by Raphael Mechoulam’s work by naming future recipients of this award the “Arcview Raphael Mechoulam Lifetime Achievement Award.”

“Cannabis research has never been more critical to the future of our industry, especially as the federal government begins processing dozens of pending applications for the steps necessary to improve access to marijuana research,” said The Arcview Group CEO and co-founder Troy Dayton. “As the first person to synthesize THC, identify the endocannabinoid system and illustrate the medicinal properties of cannabis, no one is more deserving than Raphael of our Lifetime Achievement Award. We can’t wait to see what he uncovers next.”

The Arcview Investor Forum: The Evolution of Cannabis: 2020, hosted for members of the Arcview Investor Network, will bring together the biggest fund managers, CEOs of the largest cannabis companies, and key investors in the space. In addition, Arcview’s members have selected seven cannabis companies (out of a field of over 100 applicants) that will present to investors in a ‘Shark Tank’ style format at the forum.

Space is now extremely limited to attend the Arcview Investor Forum: The Evolution of Cannabis: 2020 in New York. Accredited investors interested in attending the forum, which will include a special “Preview Day” for the first time ever on Wednesday, October 2, 2019, can do so by registering for the event at http://events.arcviewgroup.com/.

About Rafael Mechoulam

Mechoulam is the first person responsible for isolating cannabinoids, including Tetrahydrocannabinol (THC) and anandamide, which led to the breakthrough discoveries of the endocannabinoid system and the total synthesis of cannabinoids in the cannabis plant. His laboratory has worked on the chemistry, pharmacology and clinical effects of natural products, including cannabis, for more than 50 years. Mechoulam’s current research focuses on the numerous anandamide-like compounds in mammals, many of which are involved in basic biological reactions, such as bone formation, blood vessel relaxation, head trauma and addiction in addition and the development of novel cannabinoids and anandamide-like compounds as pharmaceutical drugs.

Mechoulam was born in Sofia, Bulgaria on November 5, 1930, and after the communist takeover of hitherto pro-German Bulgaria in 1944, he studied chemical engineering. Mechoulam received his M.Sc. in biochemistry from the Hebrew University of Jerusalem (1952) and his Ph.D. at the Weizmann Institute, Rehovot (1958) with a thesis on the chemistry of steroids. After postdoctoral studies at the Rockefeller Institute, New York (1959–60), he was on the scientific staff of the Weizmann Institute (1960–65) before moving to the Hebrew University of Jerusalem, where he became professor (1972) and Lionel Jacobson Professor of Medicinal Chemistry until 1975. Additionally, he was rector (1979–82) and pro-rector (1983–85). In 1994, he was elected as a member of the Israel Academy of Sciences. Raphael has been the recipient of numerous awards, including the Israel Prize in Exact Sciences - Chemistry (2000), the NIDA Discovery Award (2011), the EMET Prize in Exact Sciences - Chemistry (2012) and the Rothschild Prize in Chemical Sciences and Physical Sciences (2012).

About The Arcview Group

The Arcview Group is the leading investment and market research firm focused on connecting high-net-worth individuals, institutional investors and money managers with the investment opportunities, key players and indispensable insights to realize their goals in the cannabis sector. Founded in 2010 and listed recently by Forbes as one of the top five financial firms in the cannabis industry, investors in the Arcview Investor Network have invested more than $270 million in at least 215 Arcview-curated companies. Arcview Market Research has published more than 20 market reports, which forecast and analyze the rapidly evolving industry. Arcview co-founded and partnered with Canopy Boulder, the first seed-stage mentor-driven business accelerator that has graduated more than 100 companies. Arcview is also co-founder of Cannasure Insurance Services, the leading provider of business insurance to the cannabis industry. For more information, visit arcviewgroup.com.